Purple Biotech Ltd.

Regulatory Filings • May 11, 2018

_________ false

����� ����� ��"�	2 380
KITOV PHARMA LTD
Corporation no: 520031238	10994
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	11/05/2018
	www.isa.gov.il			www.tase.co.il				Reference:	2018-02-047335	Time of broadcast: 15:47 15:44:42

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	Delay the publication of a report	_________	_________

1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2018 Commission File Number: 001-37643 KITOV PHARMA LTD. Consensi� Commercialization Agreement for China. Kitov is entitled to receive up to an aggregate of $3.5 million for U.S. FDA approval of Consensi�, which has a PDUFA date of May 31, 2018, and for China regulatory milestones; up to an aggregate of $6.0 million for predefined commercial milestones; and up to 12% royalties on net sales. The initial term of the definitive agreement with Changshan Pharma is for ten years from the date of first commercial sale and shall automatically renew for additional one-year terms. Press Release: �Kitov Announces Consensi� Commercialization Agreement for China�

f6k051118_kitovpharmaltdEDGAR4_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 01/05/2018
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101   , Israel Tel: 03-9333121 , Fax: 03-5097196
E-mail address: info@kitovpharma.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: BEN-TZVI ABRAHAM SHLOMO Position of Signatory in the reporting corporation: Chief Legal Officer & Secretary Name of Employer Company:
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: avraham@kitovpharma.com 1
Israel